
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT
I Background Information:
A 510(k) Number
K222116
B Applicant
Siemens Healthcare Diagnostics Inc.
C Proprietary and Established Names
AtellicaÂ® CI Analyzer, AtellicaÂ® IMThyroid Stimulating Hormone 3-Ultra (TSH3-UL),
AtellicaÂ® CH Albumin BCP (AlbP)
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 862.1690 -
CH - Clinical
JLW Class II Thyroid Stimulating
Chemistry
Hormone Test System
21 CFR 862.1035 - CH - Clinical
CJW Class II
Albumin test system Chemistry
21 CFR 862.2160 -
Discrete photometric CH - Clinical
JJE Class I
chemistry analyzer for Chemistry
clinical use
II Submission/Device Overview:
A Purpose for Submission:
Addition of previously cleared assays to a new instrument
B Measurand:
Thyroid Stimulating Hormone, Albumin
C Type of Test:
Quantitative, photometry for albumin
Quantitative, chemiluminescence immunoassay for thyroid stimulating hormone
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
JLW			Class II	21 CFR 862.1690 -
Thyroid Stimulating
Hormone Test System			CH - Clinical
Chemistry
CJW			Class II	21 CFR 862.1035 -
Albumin test system			CH - Clinical
Chemistry
JJE			Class I	21 CFR 862.2160 -
Discrete photometric
chemistry analyzer for
clinical use			CH - Clinical
Chemistry

--- Page 2 ---
B Indication(s) for Use:
The AtellicaÂ® CI Analyzer is an automated, integrated system designed to perform in vitro
diagnostic tests on clinical specimens. The system is intended for the qualitative and
quantitative analysis of various body fluids, using photometric, turbidimetric,
chemiluminescent, and integrated ionselective electrode technology for clinical use.
The AtellicaÂ® IM Thyroid Stimulating Hormone 3â€‘Ultra (TSH3â€‘UL) assay is for in vitro
diagnostic use in the quantitative determination of thyroid-stimulating hormone (TSH,
thyrotropin) in human serum and plasma (EDTA and lithium heparin) using the AtellicaÂ® CI
Analyzer. Measurements of thyroid stimulating hormone produced by the anterior pituitary
are used in the diagnosis of thyroid or pituitary disorders.
The AtellicaÂ® CH Albumin BCP (AlbP) assay is for in vitro diagnostic use in the
quantitative measurement of albumin in human serum and plasma (lithium heparin,
potassium EDTA) using the AtellicaÂ® CI Analyzer. Albumin measurements are used in the
diagnosis and treatment of numerous diseases primarily involving the liver or kidneys.
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
AtellicaÂ® CI analyzer
IV Device/System Characteristics:
A Device Description:
AtellicaÂ® CI Analyzer
The AtellicaÂ® CI Analyzer is an automated, integrated system designed to perform in vitro
diagnostic tests on clinical specimens. The system is intended for the qualitative and quantitative
analysis of various body fluids, using photometric, turbidimetric, chemiluminescent, and
integrated ion selective electrode technology for clinical use.
The AtellicaÂ® CI Analyzer with AtellicaÂ® Rack Handler supports both clinical chemistry (CH)
and Immunoassay (IM) features and contains all the necessary hardware, electronics, and
software to automatically process samples and generate results, including sample and reagent
dispensing, mixing, and incubating.
AtellicaÂ® IM TSH3-UL
The AtellicaÂ® IM TSH3-UL assay is performed using the AtellicaÂ® IMTSH3â€‘UL ReadyPackÂ®
primary reagent pack, AtellicaÂ® IM Multiâ€‘Diluent 15 ReadyPack ancillary reagent pack, and the
AtellicaÂ® IM TSH3-UL CAL (calibrator) on the AtellicaÂ® CI Analyzer.
The AtellicaÂ® IMTSH3â€‘UL ReadyPackÂ® Primary Reagent Pack consists of the following:
â€¢ Lite Reagent:
4.2 mL/reagent pack, Bovine serum albumin (BSA) conjugated to mouse monoclonal
anti-TSH (~0.3 Î¼g/mL) labeled with acridinium ester in HEPES buffered saline; mouse
IgG; BSA; goat serum; surfactant; preservatives
2

--- Page 3 ---
â€¢ Solid Phase:
16.5 mL/reagent pack, Mouse monoclonal anti-fluorescein antibody covalently linked to
paramagnetic particles (~85 Î¼g/mL) in buffer; stabilizers; surfactant; preservatives
â€¢ Ancillary Well Reagent:
4.2 mL/reagent pack, FITC conjugated to mouse monoclonal anti-TSH (~3 Î¼g/mL) in
buffer; stabilizers; surfactant; preservatives
The AtellicaÂ® IM Multiâ€‘Diluent 15 ReadyPack ancillary reagent pack consists of 25.0 mL/pack
of Equine serum; sodium azide (0.1%); preservatives
The AtellicaÂ® IM TSH3-UL CAL (calibrator) consists of 2.0 mL/vial; buffer; equine serum;
sodium azide (< 0.1%); preservatives
AtellicaÂ® CH Albumin BCP (AlbP)
The AtellicaÂ® CH Albumin BCP (AlbP) assay, also referred to as the AtellicaÂ® CH AlbP, is an
assay system performed using the AtellicaÂ® CH AlbP Reagent Pack and the AtellicaÂ® CH AlbP
CAL (calibrator) on the AtellicaÂ® CI Analyzer.
The AtellicaÂ® CH AlbP Reagent Pack consists of two wells of reagent 1: 18.3 mL Bromocresol
Purple (1.1 mmol/L), acetate buffer, surfactant, microbial inhibitor. Materials required, but not
provided, consist of the AtellicaÂ® CH AlbP CAL (calibrator).
Principle of Operation:
AtellicaÂ® IM TSH3-UL assay
The AtellicaÂ® IM TSH3-UL assay employs anti-FITC (fluorescein isothiocyanate) monoclonal
antibody covalently bound to paramagnetic particles, a FITC-labeled anti-TSH capture mouse
monoclonal antibody, and a tracer consisting of a proprietary acridinium ester and an anti-TSH
mouse monoclonal antibody conjugated to bovine serum albumin (BSA) for chemiluminescent
detection. A direct relationship exists between the amount of TSH present in the patient sample,
with a sample volume of 75 Î¼L, and the amount of relative light units (RLUs) detected by the
system.
AtellicaÂ® CH AlbP assay
The AtellicaÂ® CH AlbP assay employs photometric determination to measure albumin. Albumin
binds to bromocresol purple (BCP) dye in mildly acidic pH to form an albumin-BCP complex.
An increase in absorbance at 596/694 nm is proportional to the concentration of albumin in the
sample, when a sample volume of 4 Î¼L is tested.
B Instrument Description Information:
1. Instrument Name:
AtellicaÂ® CI Analyzer
2. Specimen Identification:
The specimen is held in a tube with a barcode label. The system identifies the specimen by
scanning the barcode. This is the primary use case for sample identification. The system also
3

--- Page 4 ---
supports manual entry of sample IDs to support the needs of the customer and the use of a
Laboratory Information System (LIS).
3. Specimen Sampling and Handling:
For CH assays, the sample volume on the AtellicaÂ® CI Analyzer is 4â€“50Î¼L. For IM assays,
the sample volume on the AtellicaÂ® CI Analyzer is 10â€“100 Î¼L.
Specimen sampling and handling procedures are analyte specific and documented in the
respective reagent method sheets.
4. Calibration:
Calibration methods and procedures are analyte specific and documented in the respective
reagent method sheets.
5. Quality Control:
Labeling recommends that at least two levels (ex: low and high) of an appropriate quality
control material be tested. Quality control procedures are analyte specific and documented in
the respective reagent method sheets.
V Substantial Equivalence Information:
A Predicate Device Name(s):
Trinidad IM Thyroid Stimulating Hormone (TSH) Assay, Trinidad IM TSH Calibrators,
Trinidad Immunoassay (IM) System
Trinidad CH system, Trinidad CH Albumin BCP reagent (Alb_P), Trinidad CH Albumin BCP
Calibrator
B Predicate 510(k) Number(s):
K151792, K151767
C Comparison with Predicate(s):
Comparison of TSH Assay:
Device & Predicate
K151792 K222116
Device(s):
Trinidad IM Thyroid
Stimulating Hormone AtellicaÂ® IM
(TSH) Assay, Trinidad Thyroid Stimulating
Device Trade Name
IM TSH Calibrators, Hormone 3-Ultra
Trinidad Immunoassay (TSH3-UL)
(IM) System
General Device
Characteristic Similarities
Quantitative
determination of
Intended Use/Indications
thyroid-stimulating Same
For Use
hormone (TSH,
thyrotropin)
4

[Table 1 on page 4]
	Device & Predicate		K151792	K222116
	Device(s):			
Device Trade Name			Trinidad IM Thyroid
Stimulating Hormone
(TSH) Assay, Trinidad
IM TSH Calibrators,
Trinidad Immunoassay
(IM) System	AtellicaÂ® IM
Thyroid Stimulating
Hormone 3-Ultra
(TSH3-UL)
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			Quantitative
determination of
thyroid-stimulating
hormone (TSH,
thyrotropin)	Same

--- Page 5 ---
Electrolyte, Photometric
Operating principle Same
and Turbidimetric
General Device
Characteristic Similarities K151792 K222116
Serum, EDTA plasma,
Sample Type Same
lithium heparin plasma
Monoclonal murine anti-
TSH antibody BSA
Detection Antibody Same
conjugate labeled with
acridinium ester (AE)
Anti-fluorescein labeled
(FITC) monoclonal
murine anti-TSH
Capture Antibody Same
antibody covalently
bound to paramagnetic
particles (PMP)
Assay range 0.008â€“150.000 Î¼IU/mL Same
General Device
Characteristic Differences
LoB(Î¼IU/mL) 0.001 LoB(Î¼IU/mL) 0.004
Detection Limit
LoD(Î¼IU/mL) 0.008 LoD(Î¼IU/mL) 0.005
Comparison of Albumin Assay:
Device & Predicate
K151767 K222116
Device(s):
Trinidad CH Albumin
AtellicaÂ® CH
BCP reagent (Alb_P),
Device Trade Name Albumin BCP
Trinidad CH Albumin
(AlbP)
BCP Calibrator
General Device
Characteristic Similarities
Quantitative
Intended Use/Indications
measurement of Same
For Use
albumin
bromocresol purple
Operating principle (BCP) dye-binding Same
method
Assay range 0.5â€“8.0 g/dL Same
Serum, plasma (lithium
Sample type heparin, potassium Same
EDTA)
General Device
Characteristic Differences
LoD (g/dL) 0.2 LoD (g/dL) 0.5
Detection Limit
LoQ (g/dL) 0.4 LoQ (g/dL) 0.5
5

[Table 1 on page 5]
Operating principle			Electrolyte, Photometric
and Turbidimetric			Same
	General Device		K151792			K222116
	Characteristic Similarities					
						
Sample Type				Serum, EDTA plasma,		Same
				lithium heparin plasma		
Detection Antibody			Monoclonal murine anti-
TSH antibody BSA
conjugate labeled with
acridinium ester (AE)			Same
Capture Antibody			Anti-fluorescein labeled
(FITC) monoclonal
murine anti-TSH
antibody covalently
bound to paramagnetic
particles (PMP)			Same
Assay range			0.008â€“150.000 Î¼IU/mL			Same
	General Device					
	Characteristic Differences					
Detection Limit			LoB(Î¼IU/mL) 0.001
LoD(Î¼IU/mL) 0.008			LoB(Î¼IU/mL) 0.004
LoD(Î¼IU/mL) 0.005

[Table 2 on page 5]
	Device & Predicate		K151767			K222116
	Device(s):					
Device Trade Name				Trinidad CH Albumin		AtellicaÂ® CH
Albumin BCP
(AlbP)
				BCP reagent (Alb_P),		
				Trinidad CH Albumin		
				BCP Calibrator		
	General Device					
	Characteristic Similarities					
Intended Use/Indications
For Use			Quantitative
measurement of
albumin			Same
Operating principle			bromocresol purple
(BCP) dye-binding
method			Same
Assay range			0.5â€“8.0 g/dL			Same
Sample type			Serum, plasma (lithium
heparin, potassium
EDTA)			Same
	General Device					
	Characteristic Differences					
Detection Limit			LoD (g/dL) 0.2
LoQ (g/dL) 0.4			LoD (g/dL) 0.5
LoQ (g/dL) 0.5

[Table 3 on page 5]
AtellicaÂ® CH
Albumin BCP
(AlbP)

--- Page 6 ---
Comparison of the Analyzers:
Device & Predicate
K151767 K222116
Device(s):
AtellicaÂ® CI
Device Trade Name Trinidad CH system
analyzer
General Device
Characteristic Similarities
Automated, clinical
chemistry analyzer
Intended Use/Indications
intended for in vitro Same
For Use
diagnostic tests on
clinical specimens
Electrolyte, Photometric
Operating principle Same
and Turbidimetric
General Device
K151767 K222116
Characteristic Differences
AtellicaÂ® CI
Software Atellica Solution
Software
Assay Capacity On-Board Up to 70 assays Up to 20 assays
Device & Predicate
K151792 K222116
Device(s):
Trinidad Immunoassay AtellicaÂ® CI
Device Trade Name
(IM) System analyzer
General Device
Characteristic Similarities
Automated,
immunoassay analyzer
Intended Use/Indications
intended for in vitro Same
For Use
diagnostic tests on
clinical specimens
Chemiluminescence
using magnetic- particle
Operating principle Same
solid phase and
chemiluminescent label
General Device
Characteristic Differences
AtellicaÂ® CI
Software Atellica Solution
Software
Assay Capacity On-Board Up to 42 assays Up to 20 assays
6

[Table 1 on page 6]
	Device & Predicate		K151767	K222116
	Device(s):			
Device Trade Name			Trinidad CH system	AtellicaÂ® CI
analyzer
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			Automated, clinical
chemistry analyzer
intended for in vitro
diagnostic tests on
clinical specimens	Same
Operating principle			Electrolyte, Photometric
and Turbidimetric	Same
	General Device		K151767	K222116
	Characteristic Differences			
Software			Atellica Solution	AtellicaÂ® CI
Software
Assay Capacity On-Board			Up to 70 assays	Up to 20 assays

[Table 2 on page 6]
	Device & Predicate		K151792	K222116
	Device(s):			
Device Trade Name			Trinidad Immunoassay
(IM) System	AtellicaÂ® CI
analyzer
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			Automated,
immunoassay analyzer
intended for in vitro
diagnostic tests on
clinical specimens	Same
Operating principle			Chemiluminescence
using magnetic- particle
solid phase and
chemiluminescent label	Same
	General Device			
	Characteristic Differences			
Software			Atellica Solution	AtellicaÂ® CI
Software
Assay Capacity On-Board			Up to 42 assays	Up to 20 assays

--- Page 7 ---
VI Standards/Guidance Documents Referenced:
â€¢ CLSI EP05-A3, Evaluation of Precision of Quantitative Measurement Procedures, Third
Edition
â€¢ CLSI EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures,
Second Edition
â€¢ CLSI EP07, Interference Testing in Clinical Chemistry, Third Edition
â€¢ CLSI EP09c, Measurement Procedure Comparison and Bias Estimation Using Patient
Samples, Third Edition
â€¢ CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement
Procedures, Second Edition
â€¢ CLSI EP28-A3c, Defining, Establishing, and Verifying Reference Intervals in the
Clinical Laboratory, Third Edition
â€¢ CLSI EP34, Establishing, and Verifying an Extended Measuring Interval through
Specimen Dilution and Spiking, First Edition
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
Repeatability and intermediate precision were evaluated following the recommendations in
the CLSI guideline EP05-A3.
Thyroid Stimulating Hormone:
Six serum samples, three EDTA plasma samples, three lithium heparin plasma samples, and
three control samples were each assayed over 20 days, in duplicate, two runs per day, for a
total of 80 results per sample tested on one instrument. The results of the 20-day precision
study are shown in the table below (n = 80 for each panel):
Mean Repeatability Within-Laboratory
Sample N ÂµIU/mL Precision
SD %CV SD %CV
ÂµIU/mL ÂµIU/mL
Serum A 80 0.017 0.0009 5.3 0.0015 8.8
Serum B 80 0.156 0.0018 1.2 0.0047 3.0
Serum C 80 1.129 0.0152 1.3 0.0262 2.3
Serum D
80 9.848 0.1213 1.2 0.1996 2.0
Serum E
80 58.362 0.6498 1.1 1.4346 2.5
Serum F
80 120.833 1.6610 1.4 3.5474 2.9
EDTA Plasma A
80 1.408 0.0170 1.2 0.0311 2.2
EDTA Plasma B
80 39.662 0.6028 1.5 0.9500 2.4
EDTA Plasma C
80 97.894 1.2965 1.3 2.8148 2.9
Heparin Plasma A
80 1.706 0.0230 1.3 0.0321 1.9
7

[Table 1 on page 7]
		Mean	Repeatability		Within-Laboratory	
Sample	N	ÂµIU/mL			Precision	
			SD	%CV	SD	%CV
			ÂµIU/mL		ÂµIU/mL	
Serum A	80	0.017	0.0009	5.3	0.0015	8.8
Serum B	80	0.156	0.0018	1.2	0.0047	3.0
Serum C	80	1.129	0.0152	1.3	0.0262	2.3
Serum D	80	9.848	0.1213	1.2	0.1996	2.0
Serum E	80	58.362	0.6498	1.1	1.4346	2.5
Serum F	80	120.833	1.6610	1.4	3.5474	2.9
EDTA Plasma A	80	1.408	0.0170	1.2	0.0311	2.2
EDTA Plasma B	80	39.662	0.6028	1.5	0.9500	2.4
EDTA Plasma C	80	97.894	1.2965	1.3	2.8148	2.9
Heparin Plasma A	80	1.706	0.0230	1.3	0.0321	1.9

--- Page 8 ---
Mean Repeatability Within-Laboratory
Sample N ÂµIU/mL Precision
SD %CV SD %CV
ÂµIU/mL ÂµIU/mL
Heparin Plasma B
80 40.719 0.4539 1.1 0.8526 2.1
Heparin Plasma C
80 97.533 1.4809 1.5 3.1898 3.3
Control 1 80 0.387 0.0057 1.5 0.0091 2.4
Control 2 80 4.745 0.0812 1.7 0.1136 2.4
Control 3 80 32.012 0.4122 1.3 0.7244 2.3
Albumin:
Three serum samples and one Serum QC sample were each assayed over 20 days, in
duplicate, two runs per day, for a total of 80 results per sample tested on one instrument. The
results of the 20-day precision study are shown in the table below (n = 80 for each panel):
Mean Repeatability Within-Laboratory
Sample N g/dL Precision
SD %CV SD %CV
g/dL g/dL
Serum 1 80 2.7 0.03 1.1 0.06 2.2
Serum QC 1 80 3.1 0.04 1.3 0.08 2.6
Serum 2 80 3.6 0.03 0.8 0.09 2.5
Serum 3 80 7.1 0.04 0.6 0.12 1.7
A reproducibility study was conducted using three serum samples, where the samples were
run in five replicates, on three instruments, using three reagent lots, for five days. The results
of the reproducibility (five days) study are shown in the table below (n = 225 for each panel):
Mean Repeatability Reproducibility
Sample N g/dL
SD %CV SD %CV
g/dL g/dL
Serum 1 225 2.7 0.03 1.2 0.05 1.9
Serum 2 225 3.7 0.03 0.9 0.05 1.4
Serum 3 225 7.1 0.04 0.6 0.11 1.5
Mean Between-Day Between- Between-Lot
Sample N g/dL Instrument
SD %CV SD %CV SD %CV
g/dL g/dL g/dL
Serum 1 225 2.7 0.03 1.3 0.02 0.7 0.01 0.2
Serum 2 225 3.7 0.03 0.9 0.01 0.4 0.01 0.3
Serum 3 225 7.1 0.06 0.9 0.00 0.0 0.07 1.1
8

[Table 1 on page 8]
		Mean	Repeatability		Within-Laboratory	
Sample	N	ÂµIU/mL			Precision	
			SD	%CV	SD	%CV
			ÂµIU/mL		ÂµIU/mL	
Heparin Plasma B	80	40.719	0.4539	1.1	0.8526	2.1
Heparin Plasma C	80	97.533	1.4809	1.5	3.1898	3.3
Control 1	80	0.387	0.0057	1.5	0.0091	2.4
Control 2	80	4.745	0.0812	1.7	0.1136	2.4
Control 3	80	32.012	0.4122	1.3	0.7244	2.3

[Table 2 on page 8]
		Mean	Repeatability		Within-Laboratory	
Sample	N	g/dL			Precision	
			SD	%CV	SD	%CV
			g/dL		g/dL	
Serum 1	80	2.7	0.03	1.1	0.06	2.2
Serum QC 1	80	3.1	0.04	1.3	0.08	2.6
Serum 2	80	3.6	0.03	0.8	0.09	2.5
Serum 3	80	7.1	0.04	0.6	0.12	1.7

[Table 3 on page 8]
		Mean	Repeatability		Reproducibility	
Sample	N	g/dL				
			SD	%CV	SD	%CV
						
			g/dL		g/dL	
Serum 1	225	2.7	0.03	1.2	0.05	1.9
Serum 2	225	3.7	0.03	0.9	0.05	1.4
Serum 3	225	7.1	0.04	0.6	0.11	1.5

[Table 4 on page 8]
		Mean	Between-Day		Between-		Between-Lot	
Sample	N	g/dL			Instrument			
			SD	%CV	SD	%CV	SD	%CV
			g/dL		g/dL		g/dL	
Serum 1	225	2.7	0.03	1.3	0.02	0.7	0.01	0.2
Serum 2	225	3.7	0.03	0.9	0.01	0.4	0.01	0.3
Serum 3	225	7.1	0.06	0.9	0.00	0.0	0.07	1.1

--- Page 9 ---
2. Linearity:
Thyroid Stimulating Hormone:
A high TSH serum pool was created using native samples with known high TSH values. The
high TSH serum pool was serially diluted with a low sample TSH pool (i.e. TSH-free serum
sample) to create 14 TSH serum samples distributed across the analytical measuring interval.
All samples were run in quintuplet on one AtellicaÂ® CH Analyzer, with 3 reagent lots. The
results of the linearity study support the claimed measuring interval of 0.008 Î¼IU/mL to
150.000 Î¼IU/mL.
Dilution Recovery:
Studies were conducted in accordance with the CLSI guideline EP34. The dilution study
results support the sponsorâ€™s labeling claims that samples with TSH concentrations above the
150 Î¼IU/mL may be diluted automatically by the analyzer (i.e. 1:2 and 1:5) with a sample
volume of 100 Î¼L and 80 Î¼L, respectively for serum and plasma samples.
Albumin:
A high serum pool was created by spiking native samples with albumin (bovine serum
albumin powder from Sigma Aldrich). The low albumin serum pool was created by diluting
serum samples with CH diluent. The high serum pool was diluted with the low serum pool to
create nine albumin serum samples distributed across the analytical measuring interval. All
samples were run in quintuplet on one AtellicaÂ® CI Analyzer, with one reagent lot. The
results of the linearity study support the claimed measuring interval of 0.5 g/dL to 8.0 g/dL.
3. Analytical Specificity/Interference:
Interference testing was conducted in accordance with CLSI guideline EP07â€‘ed3.
Thyroid Stimulating Hormone:
Two human serum specimen pools with native analyte, concentrations of approximately 0.8
and 9.0 Î¼IU/mL, were supplemented with potentially interfering compounds at levels listed
in the table below. Significant interference was defined as more than Â±10% bias as compared
to the control results. The results of the interference study are summarized in the table
below:
Maximum concentration tested that
Substances
demonstrated no significant
interference
Hemoglobin 500 mg/dL
Conjugated bilirubin 40 mg/dL
Unconjugated bilirubin 40 mg/dL
Lipemia (Intralipid) 1000 mg/dL
Biotin 0.35 mg/dL
Acetaminophen 15.60 mg/dL
N-Acetylcysteine 15.00 mg/dL
Acetylsalicylic acid 3.00 mg/dL
Ampicillin 7.50 mg/dL
Ascorbic Acid 5.25 mg/dL
9

[Table 1 on page 9]
Substances	Maximum concentration tested that
	demonstrated no significant
	
	interference
Hemoglobin	500 mg/dL
Conjugated bilirubin	40 mg/dL
Unconjugated bilirubin	40 mg/dL
Lipemia (Intralipid)	1000 mg/dL
Biotin	0.35 mg/dL
Acetaminophen	15.60 mg/dL
N-Acetylcysteine	15.00 mg/dL
Acetylsalicylic acid	3.00 mg/dL
Ampicillin	7.50 mg/dL
Ascorbic Acid	5.25 mg/dL

--- Page 10 ---
Maximum concentration tested that
Substances
demonstrated no significant
interference
Carbimazole 3.00 mg/dL
Cefoxitin 495.00 mg/dL
Cyclosporine 0.18 mg/dL
Doxycycline 1.80 mg/dL
Heparin 7500 units/dL
Ibuprofen 21.90 mg/dL
Levodopa 0.75 mg/dL
Levothyroxine 0.0429 mg/dL
Liothyronine 0.0075 mg/dL
Methimazole 8.00 mg/dL
Methyldopa 2.25 mg/dL
Metronidazole 12.30 mg/dL
Octreotide 0.03 mg/dL
Phenylbutazone 32.10 mg/dL
Propranolol 24.00 mg/dL
Propylthiouracil 30.00 mg/dL
Rifampicin 4.80 mg/dL
Theophylline 6.00 mg/dL
Total Protein 15.0 g/dL
Cholesterol 400 mg/dL
Rheumatoid Factor 1500 IU/mL
The following information pertains to limitations of the assay:
i. Patient samples may contain heterophilic antibodies that could react in immunoassays
to give falsely elevated or depressed results. This assay is designed to minimize
interference from heterophilic antibodies.
ii. Do not use samples that contain fluorescein. Fluorescein levels > 0.24 Î¼g/mL may
decrease results in this assay. Evidence suggests that patients undergoing retinal
fluorescein angiography can retain amounts of fluorescein in the body for up to 48â€“72
hours post-treatment.
In the cases of patients with renal insufficiency, including many diabetics, retention
could be much longer. Such samples can produce falsely depressed values when tested
with this assay and should not be tested. Testing of samples spiked with a theoretical
maximum level of fluorescein (250 Î¼g/mL) used in these patients have resulted in
TSH levels < 0.06 Î¼IU/mL instead of the true value of 27.99 Î¼IU/mL.
iii. As with any immuno-recognition measurement of a peptide, extremely rare genetic
variants of TSH may exhibit varying degrees of detection in this assay.
Cross-Reactivity Testing:
Cross-reactivity studies were performed to evaluate the susceptibility of the AtellicaÂ® IM
TSH3-UL assay to cross-reactivity with the following endogenous structural analogs to
human TSH: human follicle stimulating hormone (FSH), human luteinizing hormone (LH),
10

[Table 1 on page 10]
Substances	Maximum concentration tested that
	demonstrated no significant
	
	interference
Carbimazole	3.00 mg/dL
Cefoxitin	495.00 mg/dL
Cyclosporine	0.18 mg/dL
Doxycycline	1.80 mg/dL
Heparin	7500 units/dL
Ibuprofen	21.90 mg/dL
Levodopa	0.75 mg/dL
Levothyroxine	0.0429 mg/dL
Liothyronine	0.0075 mg/dL
Methimazole	8.00 mg/dL
Methyldopa	2.25 mg/dL
Metronidazole	12.30 mg/dL
Octreotide	0.03 mg/dL
Phenylbutazone	32.10 mg/dL
Propranolol	24.00 mg/dL
Propylthiouracil	30.00 mg/dL
Rifampicin	4.80 mg/dL
Theophylline	6.00 mg/dL
Total Protein	15.0 g/dL
Cholesterol	400 mg/dL
Rheumatoid Factor	1500 IU/mL

--- Page 11 ---
and human chorionic gonadotropin (hCG). Five replicates of four samples with the
following concentrations were tested: 0.3 Î¼IU/mL, 3.6 Î¼IU/mL, 51 Î¼IU/mL, and 114
Î¼IU/mL TSH. Significant cross reactivity was defined as >5% bias in expected results
compared to the control. The following cross-reactants demonstrated no reactivity at the
concentrations tested:
Cross-reactant
Cross-reactant
concentration tested
(ÂµIU/mL)
Human Chorionic 200,000
Gonadotropin
Follicle Stimulating 1,500
Hormone
Luteinizing Hormone 600
High Dose Hook Effect:
The high-dose hook effect of the AtellicaÂ® IM TSH3-UL assay on the AtellicaÂ® CI
Analyzer was assessed by testing 15 serial dilutions of human TSH, â‰¥95% pure,
reconstituted in horse serum. Each sample was tested in replicates of three. No high dose
hook effect was observed for samples containing approximately 3,000 Î¼IU/mL of TSH.
The sponsor includes the following statement in the AtellicaÂ® IM TSH3-UL assay package
insert: â€œHigh TSH concentrations can cause a paradoxical decrease in the RLUs (high-dose
hook effect). In this assay, patient samples with TSH concentrations as high as 3000 Î¼IU/mL
(mIU/L) will report > 150.000 Î¼IU/mL (mIU/L).â€
Albumin:
Two pools of serum samples (~3.5 g/dL and ~5.0 g/dL) were spiked with interfering
substances and tested in quintuplet with 3 reagent lots on one AtellicaÂ® CI Analyzer.
Interference was determined by testing controls (no interfering substance added) and
matched test sample (with interfering substance added). Significant interference was
defined as more than Â±10% bias as compared to the control results. The results of the
interference study are summarized in the table below:
Maximum concentration tested that
Substances
demonstrated no significant
interference
Hemoglobin 1000 mg/dL
Conjugated bilirubin 30 mg/dL
Unconjugated bilirubin 30 mg/dL
Lipemia (Triglycerides) 2000mg/dL
Lipemia (Intralipid) 500 mg/dL
Biotin 0.351 mg/dL
Acetaminophen 15.60 mg/dL
N-Acetylcysteine 15.00 mg/dL
11

[Table 1 on page 11]
	Cross-reactant
Cross-reactant	
	concentration tested
	
	(ÂµIU/mL)
Human Chorionic
Gonadotropin	200,000
Follicle Stimulating
Hormone	1,500
Luteinizing Hormone	600

[Table 2 on page 11]
Substances	Maximum concentration tested that
	demonstrated no significant
	
	interference
Hemoglobin	1000 mg/dL
Conjugated bilirubin	30 mg/dL
Unconjugated bilirubin	30 mg/dL
Lipemia (Triglycerides)	2000mg/dL
Lipemia (Intralipid)	500 mg/dL
Biotin	0.351 mg/dL
Acetaminophen	15.60 mg/dL
N-Acetylcysteine	15.00 mg/dL

--- Page 12 ---
Substances Maximum concentration tested that
demonstrated no significant
interference
Acetylsalicylic acid 3.00 mg/dL
Ampicillin 7.50 mg/dL
Ascorbic Acid 5.25 mg/dL
Cefoxitin 75.00 mg/dL
Cholesterol 400 mg/dL
Cyclosporine 0.18 mg/dL
Heparin 3300 IU/L
Ibuprofen 21.90 mg/dL
Immunoglobin G 5 g/dL
Levodopa 0.75 mg/dL
Rifampicin 4.80 mg/dL
Rheumatoid Factor 1500 IU/mL
Theophylline 6 mg/dL
4. Assay Reportable Range:
TSH: 0.008 Î¼IU/mL to 150.000 Î¼IU/mL.
Albumin: 0.5 g/dL to 8.0 g/dL.
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
Traceability:
AtellicaÂ® IM TSH3-UL
The AtellicaÂ® IM TSH3-UL assay and calibrators are traceable to the World Health
Organization (WHO) 3rd International Standard for human TSH (IRP 81/565). Assigned
values for calibrators are traceable to this standardization.
AtellicaÂ® CH AlbP
The AtellicaÂ® CH AlbP assay and calibrators are traceable to ERM DA470k Reference
Material.
Stability:
AtellicaÂ® IM TSH3-UL
Protocols and acceptance criteria for on-board/open vial stability studies for the AtellicaÂ® IM
TSH3-UL ReadyPack primary reagent packÂ® Lite reagent, AtellicaÂ® IMMulti-Diluent 15,
and AtellicaÂ® IMTSH-UL calibrator were reviewed and found to be acceptable to support
an on-board stability of 90 days, 7 days, and 28 days at 2-8ÂºC, respectively. The calibrator
pack and lot calibration have a stability of 63 days.
AtellicaÂ® CH AlbP
Protocols and acceptance criteria for on-board/open vial stability studies for the AtellicaÂ®
CH AlbP reagent pack were reviewed and found to be acceptable to support an on-board
stability of up to 61 days at 2-8ÂºC. The calibrator pack has a stability of 24 days, and the lot
calibration has a stability of 30 days.
12

[Table 1 on page 12]
Substances	Maximum concentration tested that
	demonstrated no significant
	interference
Acetylsalicylic acid	3.00 mg/dL
Ampicillin	7.50 mg/dL
Ascorbic Acid	5.25 mg/dL
Cefoxitin	75.00 mg/dL
Cholesterol	400 mg/dL
Cyclosporine	0.18 mg/dL
Heparin	3300 IU/L
Ibuprofen	21.90 mg/dL
Immunoglobin G	5 g/dL
Levodopa	0.75 mg/dL
Rifampicin	4.80 mg/dL
Rheumatoid Factor	1500 IU/mL
Theophylline	6 mg/dL

--- Page 13 ---
6. Detection Limit:
Detection limit studies were conducted in accordance with CLSI guideline EP17â€‘A2.
Thyroid Stimulating Hormone:
Limit of Blank:
Five samples with no detectable TSH levels were tested. The samples were tested in four
replicates, run twice a day on two AtellicaÂ® CI Analyzers using three reagent lots over five
testing days (n = 400 measurements per reagent lot). The limit of blank was estimated by the
95th percentile of 400 values for each lot. The limit of blank was determined to be 0.004
Î¼IU/mL.
Limit of Detection:
Five low- level samples were tested in four replicates, run twice a day on two AtellicaÂ® CI
Analyzers using three reagent lots over five testing days (n = 400 measurements per reagent
lot). The limit of detection was determined to be 0.008 Î¼IU/mL.
Limit of Quantitation:
Seven human serum pools with low levels of TSH were tested. The samples were tested in
duplicate, run twice a day on two AtellicaÂ® CI Analyzers using three reagent lots over 20
testing days (n = 80 measurements per reagent lot). Calibration was performed on day 1 of
the study. The limit of quantitation was defined as the value at which the within laboratory
CV is â‰¤ 20% and determined to be 0.008 Î¼IU/mL.
LoB LoD LoQ
0.004 Î¼IU/mL 0.008 Î¼IU/mL 0.008 Î¼IU/mL
Albumin:
Limit of Blank:
Five samples with no detectable albumin levels were tested. The samples were tested in six
replicates on one AtellicaÂ® CI Analyzer, using three reagent lots over three testing days (n =
90 measurements per reagent lot). The limit of blank was estimated by the 95th percentile of
90 values for each lot. The limit of blank was determined to be 0.1 g/dL for serum.
Limit of Detection:
Four low-level albumin samples were tested. The samples were tested in six replicates on
one AtellicaÂ® CI Analyzer, using three reagent lots over three testing days (n = 90
measurements per reagent lot). The Limit of Detection was determined parametrically using
the pooled standard deviation (SDL) for all samples from a given reagent lot, using the
following equation: = + , where â€œcpâ€ represents the capability potential. The
limit of detection was determined to be between 0.43-0.53 g/dL for serum, and support a
limit of detection of ğ‘³ğ‘³0ğ‘³ğ‘³.5ğ‘³ğ‘³ g/dğ‘³ğ‘³Lğ‘³ğ‘³.ğ‘³ğ‘³ ğ’„ğ’„ğ’„ğ’„ğ’„ğ’„ğ‘³ğ‘³ğ‘³ğ‘³
Limit of Quantitation:
Five serum pools with target Albumin concentrations between 0.4-0.5 g/dL were tested, four
low level serum pools were created by diluting the base serum pools with CH diluent and
one QC sample was diluted with CH diluent to serve as a control. The samples were tested
in five replicates on one AtellicaÂ® CI Analyzer, using three reagent lots over five testing
13

[Table 1 on page 13]
LoB	LoD	LoQ
0.004 Î¼IU/mL	0.008 Î¼IU/mL	0.008 Î¼IU/mL

--- Page 14 ---
days (n = 125 measurements per reagent lot). Calibration was performed on day one of the
study. The sponsor defined the LoQ as the concentration with â‰¤ 10% within-laboratory
precision.
LoB LoD LoQ
0.1 g/dL 0.5 g/dL 0.5 g/dL
7. Assay Cut-Off:
Not applicable.
8. Accuracy (Instrument):
See section VII.B.1. below.
9. Carry-Over:
Information regarding the potential impact of carry-over on the candidate device was
reviewed and determined to be acceptable.
B Comparison Studies:
1. Method Comparison with Predicate Device:
Studies were conducted in accordance with CLSI guideline EP09câ€‘ed3.
Thyroid Stimulating Hormone:
A method comparison study compared the performance of the candidate test system
(AtellicaÂ® IM TSH3-UL on the AtellicaÂ® CI Analyzer) to the performance of the predicate,
the AtellicaÂ® IM Thyroid Stimulating Hormone (TSH) assay run on the AtellicaÂ® IM
Analyzer (K151792). A total of 112 matched, native serum samples ranging from 0.013-
144.030 ÂµIU/mL were tested in duplicate using one reagent over seven days, using one
analyzer. Weighted Deming regression analysis was performed with the first replicate result.
The data is summarized in the table below:
Weighted Correlation Sample
n
Deming Coefficient Range Tested
Regression (ÂµIU/mL)
112 y = 0.96x â€“ 0.001 0.996 0.013-144.030
Albumin:
A method comparison study compared the performance of the candidate test system
(AtellicaÂ® CH AlbP assay on the AtellicaÂ® CI Analyzer) to the performance of the
predicate, the AtellicaÂ® CH Albumin BCP (AlbP) assay on the AtellicaÂ® CH Analyzer
(K151767). A total of 106 matched, native serum samples ranging from ~0.6-7.5 g/dL were
tested using one reagent lot and one analyzer over five days. Of the 106 native samples, one
sample was diluted to meet the lower end of the measuring interval and two native samples
were spiked to meet the upper end of the measuring interval. Weighted Deming regression
analysis was performed using results from the first replicate. The data is summarized in the
table below:
14

[Table 1 on page 14]
LoB	LoD	LoQ
0.1 g/dL	0.5 g/dL	0.5 g/dL

[Table 2 on page 14]
n	Weighted	Correlation	Sample
	Deming	Coefficient	Range Tested
			
	Regression		(ÂµIU/mL)
112	y = 0.96x â€“ 0.001	0.996	0.013-144.030

--- Page 15 ---
Weighted Correlation Sample
n
Deming Coefficient Range
Regression Tested (g/dL)
106 y = 0.98x + 0.0 0.999 0.6-7.5
2. Matrix Comparison:
Studies were conducted in accordance with CLSI guideline EP09câ€‘ed3.
Thyroid Stimulating Hormone:
A matrix comparison study was conducted utilizing 65 matched lithium heparin plasma,
EDTA plasma and serum samples. One native sample was excluded from the final
analysis because the results were below the assay range of detection. Seven sets of
samples were spiked with TSH to cover the upper range of the assay. The TSH values
ranged from 0.023 to 134.942 ÂµIU/mL. All samples were assayed in duplicate with one
reagent lot on one AtellicaÂ® CI Analyzer over three days. The results were analyzed
using weighted Deming regression. The first replicate of each data set was used for the
analysis. Results are summarized in the table below:
Weighted
Test Reference Correlation Sample Interval
Deming
n
Coefficient (ÂµIU/mL)
Specimen Specimen Regression
Lithium Heparin
Plasma
Serum 64 1.00x + 0.001 ÂµIU/mL 1.00 0.023-134.942
Potassium
EDTA Serum 64 1.00x - 0.001 ÂµIU/mL 1.00 0.023-134.942
Plasma
The results support the sponsorâ€™s claims for lithium heparin and potassium EDTA plasma
samples.
Albumin:
A matrix comparison study was conducted utilizing 55 matched Potassium EDTA plasma
and serum samples and 76 matched serum and lithium heparin samples. Two sets of
samples were spiked with Albumin to cover the upper range of the assay and three
sample sets were diluted with CH diluent to cover the lower range of the assay. The
Albumin values ranged from 0.5-7.9 g/dL. All samples were assayed in duplicate with
one reagent lot on one AtellicaÂ® CI Analyzer. The results were analyzed using weighted
Deming regression. The first replicate of each data set was used for the analysis. Results
are summarized in the table below:
Comparison Weighted Deming Correlation Sample range
Test Sample n
Regression Coefficient (g/dL)
sample type
Lithium Heparin
Serum 76 1.01x + 0.0 g/dL 0.995 0.5-7.9
Plasma
Potassium
Serum 55 0.99x + 0.0 g/dL 0.997 0.5-7.9
EDTA Plasma
15

[Table 1 on page 15]
n	Weighted	Correlation	Sample
	Deming	Coefficient	Range
			
	Regression		Tested (g/dL)
106	y = 0.98x + 0.0	0.999	0.6-7.5

[Table 2 on page 15]
			Weighted		
Test	Reference				
				Correlation	Sample Interval
		n			
			Deming		
				Coefficient	(ÂµIU/mL)
Specimen	Specimen				
			Regression		
					
					
Lithium Heparin
Plasma	Serum	64	1.00x + 0.001 ÂµIU/mL	1.00	0.023-134.942
Potassium
EDTA
Plasma	Serum	64	1.00x - 0.001 ÂµIU/mL	1.00	0.023-134.942

[Table 3 on page 15]
	Comparison				
			Weighted Deming	Correlation	Sample range
Test Sample		n			
			Regression	Coefficient	(g/dL)
	sample type				
					
					
Lithium Heparin
Plasma	Serum	76	1.01x + 0.0 g/dL	0.995	0.5-7.9
Potassium
EDTA Plasma	Serum	55	0.99x + 0.0 g/dL	0.997	0.5-7.9

--- Page 16 ---
The results support the sponsorâ€™s claims for lithium heparin and potassium EDTA plasma
samples.
C Clinical Studies:
1. Clinical Sensitivity:
Not Applicable.
2. Clinical Specificity:
Not Applicable.
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not Applicable.
D Clinical Cut-Off:
Not Applicable.
E Expected Values/Reference Range:
Reference intervals for the pediatric population (infants, children, and adolescents) were
established in accordance with the CLSI guideline EP28â€‘A3c.
Thyroid Stimulating Hormone:
The reference interval was previously established on the Advia Centaur System, including the
pediatric reference intervals. Verification studies were performed using the candidate device,
where testing was conducted according to CLSI Guideline EP28-A3c. The study results support
the original reference range established with the predicate device. The expected values for serum
samples are as follows:
Age Range Reference
Range
Infants (01 â€“ 23 months) 0.87 â€“ 6.15 ÂµIU/mL
Children (02 â€“ 12 years) 0.67 â€“ 4.16 ÂµIU/mL
Adolescents (13-20 years) 0.48 â€“ 4.17 ÂµIU/mL
Adults (â‰¥ 21 years) 0.55 â€“ 4.78 ÂµIU/mL
Albumin:
The reference interval for the AtellicaÂ® CH Albumin BCP (AlbP) assay was previously
established using literature in K51767, i.e. Willey DA, Savory J, Lasky F. An Evaluation of a
Revised Albumin Method for the acaÂ® discrete clinical analyzer, Du Pont Company,
Wilmington, DE, August 1982.) To verify the reference interval, a transferability and verification
study was conducted according to CLSI Guideline EP28-A3c. The study results support the cited
reference interval of 3.4-5.0 g/dL for adults for serum and plasma samples.
F Other Supportive Instrument Performance Characteristics Data:
Not applicable.
16

[Table 1 on page 16]
Age Range	Reference
	Range
Infants (01 â€“ 23 months)	0.87 â€“ 6.15 ÂµIU/mL
Children (02 â€“ 12 years)	0.67 â€“ 4.16 ÂµIU/mL
Adolescents (13-20 years)	0.48 â€“ 4.17 ÂµIU/mL
Adults (â‰¥ 21 years)	0.55 â€“ 4.78 ÂµIU/mL

--- Page 17 ---
VIII Proposed Labeling:
The labeling does support the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and does support a
substantial equivalence decision.
17